Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone

Goncharov, N. P.; Katsya, G.V.; Chagina, N. A.; Gooren, Louis

doi:10.1080/13685530802204629

Cited by 24 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sexual dysfunction associated with OSAS may also be explained by the metabolic syndrome [175,176]. Men with OSAS have lowered plasma testosterone levels [177] but this association was largely explained by adiposity in agreement with the finding that the metabolic syndrome is associated with reduced plasma testosterone values [178,175]. In a large meta-analysis of placebo-controlled trials of testosterone administration to (elderly) men [131], the frequency of sleep apnea was not significantly different between the two groups.…”

Section: Sleep Apneasupporting

confidence: 73%

Androgens and male aging: current evidence of safety and efficacy

Gooren¹

2010

Asian J Androl

View full text Add to dashboard Cite

Many signs of aging, such as sexual dysfunction, visceral obesity, impaired bone and muscle strength, bear a close resemblance to features of hypogonadism in younger men. The statistical decline of serum testosterone in aging men is solidly documented. It has been presumed that the above features of aging are related to the concurrent decline of androgens, and that correction of the lower-than-normal circulating levels of testosterone will lead to improvement of symptoms of aging. But in essence, the pivotal question whether the age-related decline of testosterone must be viewed as hypogonadism, in the best case reversed by testosterone treatment, has not been definitively resolved. Studies in elderly men with lower-than-normal testosterone report improvement of features of the metabolic syndrome, bone mineral density, of mood and of sexual functioning. But as yet there is no definitive proof of the beneficial effects of restoring testosterone levels to normal in elderly men on clinical parameters. Few of these studies meet as yet rigorous standards of scientific enquiry: double-blind, placebo-controlled design of the study. The above applies also to the assessment of safety of testosterone administration to elderly men. There is so far no convincing evidence that testosterone is a main factor in the development of prostate cancer in elderly men and guidelines for monitoring the development of prostate disease have been developed. It is of note that there are presently no long-term safety data with regard to the prostate. Polycythemia is another potential complication of testosterone treatment. It is dose dependent and can be managed with dose adjustment.

show abstract

Section: Sleep Apneasupporting

confidence: 73%

Androgens and male aging: current evidence of safety and efficacy

Gooren¹

2010

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Low testosterone levels are associated with insulin resistance, metabolic syndrome, and development of T2D (Kapoor et al, 2007; 2005; Stellato et al, 2000; Zitzmann, 2009). Obesity, T2D, and metabolic syndrome are also associated with low testosterone levels in pre-pubertal (Mogri et al, 2013) and young men (Chandel et al, 2008; Goncharov et al, 2008). …”

Section: Sex Differences In Obesitymentioning

confidence: 99%

Obesity and sex interact in the regulation of Alzheimer's disease

Moser

Pike

2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, for which a number of genetic, environmental, and lifestyle risk factors have been identified. A significant modifiable risk factor is obesity in mid-life. Interestingly, both obesity and AD exhibit sex differences and are regulated by sex steroid hormones. Accumulating evidence suggests interactions between obesity and sex in regulation of AD risk, although the pathways underlying this relationship are unclear. Inflammation and the E4 allele of apolipoprotein E have been identified as independent risk factors for AD and both interact with obesity and sex steroid hormones. We review the individual and cooperative effects of obesity and sex on development of AD and examine the potential contributions of apolipoprotein E, inflammation, and their interactions to this relationship.

show abstract

“…Individuals with OSA can have an increased incidence of visceral obesity, insulin resistance, hypertension, and cardiovascular complications such as atrial fibrillation, stroke, and cardiac ischemia [181, 183]. OSA and metabolic syndrome are also associated with increased incidence of reduced-circulating testosterone values and erectile dysfunction [184–186]. Androgens may play role in contributing to the pathogenesis of obstructive sleep apnea as there are associations between men with abnormal sleep patterns and increased visceral adiposity with low plasma testosterone values [187, 188].…”

Section: Possible Risks Of Testosterone Therapy For Elderly Menmentioning

confidence: 99%

Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

Surampudi

Wang

Swerdloff

2012

International Journal of Endocrinology

116

112

View full text Add to dashboard Cite

Hypogonadism in older men is a syndrome characterized by low serum testosterone levels and clinical symptoms often seen in hypogonadal men of younger age. These symptoms include decreased libido, erectile dysfunction, decreased vitality, decreased muscle mass, increased adiposity, depressed mood, osteopenia, and osteoporosis. Hypogonadism is a common disorder in aging men with a significant percentage of men over 60 years of age having serum testosterone levels below the lower limits of young male adults. There are a variety of testosterone formulations available for treatment of hypogonadism. Data from many small studies indicate that testosterone therapy offers several potential benefits to older hypogonadal men. A large multicenter NIH supported double blind, placebo controlled study is ongoing, and this study should greatly enhance the information available on efficacy and side effects of treatment. While safety data is available across many age groups, there are still unresolved concerns associated with testosterone therapy. We have reviewed the diagnostic methods as well as benefits and risks of testosterone replacement therapy for hypogonadism in aging men.

show abstract

Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone

Cited by 24 publications

References 21 publications

Androgens and male aging: current evidence of safety and efficacy

Androgens and male aging: current evidence of safety and efficacy

Obesity and sex interact in the regulation of Alzheimer's disease

Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

Contact Info

Product

Resources

About